Xanthine Oxidase Inhibition in Renal Transplant Recipients (XART)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01332799|
Recruitment Status : Terminated (Study was not funded)
First Posted : April 11, 2011
Results First Posted : October 15, 2019
Last Update Posted : October 15, 2019
|Condition or disease||Intervention/treatment||Phase|
|Complications of Renal Transplant||Drug: allopurinol or placebo Other: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Xanthine Oxidase Inhibition in Renal Transplant Recipients|
|Actual Study Start Date :||February 2011|
|Actual Primary Completion Date :||August 10, 2018|
|Actual Study Completion Date :||August 10, 2018|
|Active Comparator: Allopurinol||
Drug: allopurinol or placebo
Daily active drug (allopurinol administered orally) administered orally for 3 years.
|Placebo Comparator: Placebo (sugar pill)||
Sugar pill administered orally for 3 years.
- Cardiovascular Events [ Time Frame: 3 years ]Number of major cardiovascular events
- Endothelial Function [ Time Frame: 3 years ]Changes in flow-mediated dilatation of braquial artery.
- Arterial Stiffness [ Time Frame: 3 years ]Changes in pulse wave velocity.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01332799
|United States, Iowa|
|University of Iowa Hospitals and Clinics|
|Iowa City, Iowa, United States, 52240|
|Principal Investigator:||Roberto S Kalil, MD||University of Iowa|